Bliss Biopharmaceutical focuses on the research and development of innovative biopharmaceuticals, particularly in the field of anti-tumor therapies. The company has established a comprehensive preclinical research platform that encompasses the design and screening of lead antibodies, genetic engineering of conjugated antibodies, and the design of small molecule payloads and linkers. Utilizing advanced techniques such as BLI, ELISA, FACS, and cellular assays, Bliss Biopharmaceutical evaluates the affinity and specificity of antibodies, assesses the stability and cytotoxicity of antibody-drug conjugates (ADCs), and conducts efficacy and safety evaluations in animal models. This rigorous approach aims to identify and develop biopharmaceuticals with high therapeutic potential.

In addition to its preclinical capabilities, Bliss Biopharmaceutical has developed a high-throughput, quality-driven process development platform that spans the entire lifecycle of biopharmaceutical development. This includes candidate molecule evaluation, high-expression cell line development, and the optimization of cell culture, purification, and formulation processes, all supported by Good Manufacturing Practice (GMP) standards. The company employs state-of-the-art automated equipment and digital management systems to ensure efficient and stable production of antibodies and ADCs, adhering to the quality standards set by regulatory bodies such as the FDA, EMA, and NMPA. This integrated approach enables Bliss Biopharmaceutical to maintain stringent quality control and traceability throughout the production process.

China

Bliss Biopharmaceutical (Hangzhou) Co., Ltd. is a clinical-stage biotech company dedicated to the discovery, development, and commercialization of anti-tumor biotherapeutics. With the core value of 'Together, We Improve Human Health,' the company focuses on multi-level collaborations and developments to advance its mission.

Cancer

Bliss Biopharmaceutical

Breast cancer

Gastric cancer

Lung cancer

Urothelial cancer

BB-1701 (Joint development w/ Eisai)

Antibodies

Biologics

7th Floor, Building 9, Heda Yaogu Phase 3, Qiantang District, Hangzhou City, Zhejiang Province, China

Antibody Drug Conjugates

Equipment

Small Molecule Pharmaceuticals

Therapeutic

Bliss Biopharmaceutical

Company Details